Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

Indications are restrictive and reflect the inclusion criteria of the INNOVATE trial, which enrolled individuals with asthma taking high-dose ICS + LABA and additional controller medications. [68] ...

Albuterol/budesonide significantly reduced the risk of severe asthma exacerbations vs albuterol alone in mild asthma based on BATURA results.

Respiratory infections represent the most common asthma exacerbation trigger, yet many patients lack clear protocols for adjusting management during these high-risk periods.

The highest dose of amlitelimab missed the primary endpoint of reducing severe asthma exacerbations at Week 48.

Phase 2b study to evaluate novel inhaled therapeutic in patients with inadequately controlled asthma despite medium-to-high dose ICS/LABA therapy ...

Background Evidence regarding high-dose inhaled corticosteroids (HDICS) in asthma exacerbations in adults is insufficient. This study compares the treatment outcomes of HDICS as add-on therapy to the ...

The researchers found that both ICS-containing relievers were associated with fewer severe exacerbations compared with SABA alone (risk ratios, 0.65 and 0.84 for ICS-formoterol and ICS-SABA ...

Data were included from 27 randomized clinical trials with 50,496 adult and pediatric patients. The researchers found that both ICS-containing relievers were associated with fewer severe exacerbations ...

After a severe asthma exacerbation, going from medium- to high-dose ICS, vs staying at the medium dose, was linked to a higher AAER and shorter time to exacerbation.

Short-term ICS use in asthma, at moderate to high doses daily, may lead to significant but uncommon risk for adverse CV and pulmonary outcomes.